Checkmate 9ER: A New Arrow in Our Quiver

The results of Phase 3 Checkmate 9ER trial are in! The 9ER trial evaluated the combination of Nivolumab (“Nivo”) and Cabozantinib (“Cabo”). This trial compared the combo to Sunitinib (“Sutent”) in patients who had not previously been on a drug and who had disease that had spread or metastasized.

Nivo is an immunotherapy agent that helps your immune system recognize and mobilize your T-cells to attack the cancer cells. Cabo is a TKI (tyrosine kinase inhibition) drug. The combo improved progression free survival (PFS), meaning the cancer did not progress as quickly compared to the other drug. It also improved OS (overall survival) in patients previously untreated. There were 651 patients in the trial. Nivo and Cabo are each approved by the FDA. This new combo is not yet approved, but will likely be approved in the near future. Other good news is that patient’s toxicity to the drug combo and their quality of life was improved. As soon as this combination is approved, it will give patients another option in their arsenal to battle mRCC.

Read the 2020 ESMO News Release here.

WHO WE ARE →

WHAT WE DO →

OUR STORIES →

THE KIDNEY CANCER COMMUNITY →

SCIENTIFIC ADVISORY BOARD →

KIDNEYCAN NEWS →

DONATE →

CONTACT →

Latest News

Dr. John T. Wilson: “A Lot of Reason to Hope”

Dr. John T. Wilson: “A Lot of Reason to Hope”

Researcher Spotlight: Dr. John T. Wilson Giving Patients "A Lot of Reason to Hope" At KidneyCAN, we have the pleasure of meeting and working with talented researchers from all over the world. We want to share some of the insights and experiences of one such researcher today, Dr. John T. Wilson,...

JOIN OUR COMMUNITY →

RAISING AWARENESS →

BE AN ADVOCATE →

DISTRICT DAYS →

KIDNEYCAN NEWS →

DONATE →

CONTACT →

Latest News

Dr. John T. Wilson: “A Lot of Reason to Hope”

Dr. John T. Wilson: “A Lot of Reason to Hope”

Researcher Spotlight: Dr. John T. Wilson Giving Patients "A Lot of Reason to Hope" At KidneyCAN, we have the pleasure of meeting and working with talented researchers from all over the world. We want to share some of the insights and experiences of one such researcher today, Dr. John T. Wilson,...

FACING KIDNEY CANCER →

DIAGNOSIS →

BUILDING A CARE TEAM →

LEARN ABOUT CLINICAL TRIALS →

LIVING WELL WITH KIDNEY CANCER →

DONATE →

CONTACT →

Latest News

World Kidney Cancer Day 2021: We Need to Talk About How We’re Feeling

World Kidney Cancer Day 2021: We Need to Talk About How We’re Feeling

On June 17th, people from all around the world came together to participate in activities for #WorldKidneyCancerDay, and we’re proud to share what KidneyCAN did in partnership with the IKCC and many other partners from the kidney cancer community. Our goal each year on World Kidney Cancer Day is...

KCRS →

RESEARCH OPPORTUNITIES →

ADVOCATE WITH KIDNEYCAN →

KIDNEYCAN NEWS →

DONATE →

CONTACT →

Latest News

Dr. John T. Wilson: “A Lot of Reason to Hope”

Dr. John T. Wilson: “A Lot of Reason to Hope”

Researcher Spotlight: Dr. John T. Wilson Giving Patients "A Lot of Reason to Hope" At KidneyCAN, we have the pleasure of meeting and working with talented researchers from all over the world. We want to share some of the insights and experiences of one such researcher today, Dr. John T. Wilson,...

SUPPORT OUR WORK →

FUNDRAISE FOR KIDNEYCAN →

DONATE →

CONTACT →

Latest News

World Kidney Cancer Day 2021: We Need to Talk About How We’re Feeling

World Kidney Cancer Day 2021: We Need to Talk About How We’re Feeling

On June 17th, people from all around the world came together to participate in activities for #WorldKidneyCancerDay, and we’re proud to share what KidneyCAN did in partnership with the IKCC and many other partners from the kidney cancer community. Our goal each year on World Kidney Cancer Day is...